Association between RAGE variants and the susceptibility to atherosclerotic lesions in Chinese Han population

Zhang,Xiaolin; Cheng,Minghui; Tong,Fangnian; Su,Xue

doi:10.3892/etm.2019.7163

Association between RAGE variants and the susceptibility to atherosclerotic lesions in Chinese Han population

Authors:
- Xiaolin Zhang
- Minghui Cheng
- Fangnian Tong
- Xue Su
View Affiliations

Affiliations: Department of Cardiology, Shenyang Military General Hospital, Shenyang, Liaoning 110840, P.R. China
Published online on: January 9, 2019 https://doi.org/10.3892/etm.2019.7163
Pages: 2019-2030
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Receptor for advanced glycation end products (RAGE) is a major proinflammatory receptor and its role in atherosclerosis has only been emphasized recently. Increasing evidence has demonstrated an association between RAGE and the susceptibility to atherosclerosis development. Therefore, the role of RAGE in atherogenesis and the possible impact of genetic variations in RAGE on the atherosclerotic process in subjects with coronary artery disease (CAD) was investigated in the present study. The RAGE expression in carotid specimens was analyzed by immunohistochemistry and sequence variations of the RAGE gene selected from the Hapmap database were also screened. The plasma levels of S100 calcium binding protein B (S100B) were determined by ELISA. Immunohistochemical staining of tissue samples demonstrated an increased RAGE expression in atherosclerotic carotid plaques compared with that in normal arteries. Furthermore, compared with the corresponding wild‑type genotype, the rs2269422 single‑nucleotide polymorphism of RAGE was associated with the susceptibility of patients with CAD to atherosclerosis. Furthermore, reverse transcription polymerase chain reaction and western blot analyses indicated increased coronary artery RAGE mRNA levels and protein expression, respectively, in CAD patients vs. control subjects. Furthermore, the plasma levels of S100B in CAD patients that were carriers of the AA/AT genotype of the rs2269422 variant of RAGE was increased compared with that in TT genotype carriers; as this was also identified in control subjects, it may not be CAD‑specific. The RAGE rs2269422 variant is therefore significantly associated with an increased occurrence of CAD in the present Han Chinese population. Thus, RAGE variants significantly impact the risk of CAD in Han Chinese subjects.

View Figures

View References

1	Kriszbacher I, Koppan M and Bodis J: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 353:429–430. 2005. View Article : Google Scholar : PubMed/NCBI
2	Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, Chasman DI, Baber U, Mehran R, Rader DJ, et al: Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 375:2349–2358. 2016. View Article : Google Scholar : PubMed/NCBI
3	Abaci A: Management of cardiovascular risk factors for primary prevention: Evaluation of Turkey results of the EURIKA study. Turk Kardiyol DernArs. 40:135–142. 2012. View Article : Google Scholar
4	Arbab-Zadeh A and Fuster V: The myth of the ‘vulnerable plaque’: Transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. J Am Coll Cardiol. 65:846–855. 2015. View Article : Google Scholar : PubMed/NCBI
5	Bjorkegren JLM, Kovacic JC, Dudley JT and Schadt EE: Genome-wide significant loci: How important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders. J Am Coll Cardiol. 65:830–845. 2015.PubMed/NCBI
6	Gao J, Deng L, Wang Y, Shi Y, Xiao X, Zheng X, Ren H and Xu D: Relationship between RAGE gene polymorphisms and cardiovascular disease prognosis in the Chinese Han population. Mol Genet Genomics. 292:1139–1149. 2017. View Article : Google Scholar : PubMed/NCBI
7	Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto T, Oda N, Hidaka T, Kihara Y, et al: Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care. 38:119–125. 2015. View Article : Google Scholar : PubMed/NCBI
8	Katakami N: Can soluble receptor for advanced glycation end-product (sRAGE) levels in blood be used as a predictor of cardiovascular diseases? Atherosclerosis. 266:223–225. 2017. View Article : Google Scholar : PubMed/NCBI
9	Nam MH, Son WR, Lee YS and Lee KW: Glycolaldehyde-derived advanced glycation end products (glycol-AGEs)-induced vascular smooth muscle cell dysfunction is regulated by the AGES-receptor (RAGE) axis in endothelium. Cell Commun Adhes. 22:67–78. 2015. View Article : Google Scholar : PubMed/NCBI
10	Puri R, Nicholls SJ, Shao M, Kataoka Y, Uno K, Kapadia SR, Tuzcu EM and Nissen SE: Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 65:1273–1282. 2015. View Article : Google Scholar : PubMed/NCBI
11	Reichert S, Triebert U, Santos AN, Hofmann B, Schaller HG, Schlitt A and Schulz S: Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease. Atherosclerosis. 266:234–239. 2017. View Article : Google Scholar : PubMed/NCBI
12	Rowisha M, El-Batch M, El Shikh T, El Melegy S and Aly H: Soluble receptor and gene polymorphism for AGE: Relationship with obesity and cardiovascular risks. Pediatr Res. 80:67–71. 2016. View Article : Google Scholar : PubMed/NCBI
13	Ligthart S, Sedaghat S, Ikram MA, Hofman A, Franco OH and Dehghan A: EN-RAGE: A novel inflammatory marker for incident coronary heart disease. Arterioscler Thromb Vasc Biol. 34:2695–2699. 2014. View Article : Google Scholar : PubMed/NCBI
14	American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine; Society for Vascular Surgery, ; Fleisher LA, Beckman JA, et al: 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol. 54:e13–e118. 2009. View Article : Google Scholar : PubMed/NCBI
15	Elisaf M, Tzouvelekis E and Nikas N; Greek EURIKA Investigators, : Primary prevention of cardiovascular disease in Greece: Greek results of the EURIKA study. Hellenic J Cardiol. 55:217–226. 2014.PubMed/NCBI
16	Ford TJ, Rocchiccioli P, Good R, McEntegart M, Eteiba H, Watkins S, Shaukat A, Lindsay M, Robertson K, Hood S, et al: Systemic microvascular dysfunction in microvascular and vasospastic angina. Eur Heart J. 1–12. 2018.PubMed/NCBI
17	Ong P, Athanasiadis A and Sechtem U: Treatment of angina pectoris associated with coronary microvascular dysfunction. Cardiovasc Drugs Ther. 30:351–356. 2016. View Article : Google Scholar : PubMed/NCBI
18	Loffler AI and Bourque JM: Coronary microvascular dysfunction, microvascular angina, and management. Curr Cardiol Rep. 18:12016. View Article : Google Scholar : PubMed/NCBI
19	Ezhumalai B, Ananthakrishnapillai A, Selvaraj RJ, Satheesh S and Jayaraman B: Cardiac syndrome X: Clinical characteristics revisited. Indian Heart J. 67:328–331. 2015. View Article : Google Scholar : PubMed/NCBI
20	Chhabra L and Kowlgi NG: Low incidence of diabetes mellitus in coronary microvascular dysfunction: An intriguing association. JACC Cardiovasc Interv. 9:395–396. 2016. View Article : Google Scholar : PubMed/NCBI
21	Suzuki H: Different definition of microvascular angina. Eur J Clin Invest. 45:1360–1366. 2015. View Article : Google Scholar : PubMed/NCBI
22	Morrison AC, Fu YP and O'Donnell CJ; Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Subclinical Atherosclerosis and CHD Working Working, : Working Group: Variants in ANGPTL4 and the risk of coronary artery disease. N Engl J Med. 375:23032016. View Article : Google Scholar : PubMed/NCBI
23	Liu Y, Tian X, Li Y, Liu D, Liu M, Zhang X, Zhang Q, Yan C and Han Y: Up-Regulation of CREG expression by the transcription factor GATA1 inhibits high glucose- and high palmitate-induced apoptosis in human umbilical vein endothelial cells. PLoS One. 11:e01548612016. View Article : Google Scholar : PubMed/NCBI
24	Cai W, Tao J, Zhang X, Tian X, Liu T, Feng X, Bai J, Yan C and Han Y: Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease. Arterioscler Thromb Vasc Biol. 34:1933–1941. 2014. View Article : Google Scholar : PubMed/NCBI
25	Okon I, Ding Y and Zou MH: Ablation of interferon regulatory factor 3 promotes the stability of atherosclerotic plaques. Hypertension. 69:407–408. 2017. View Article : Google Scholar : PubMed/NCBI
26	Huang M, Han Y, Zhang X, Pei F, Deng J, Kang J and Yan C: An intron polymorphism in the CXCL16 gene is associated with increased risk of coronary artery disease in Chinese Han population: A large angiography-based study. Atherosclerosis. 210:160–165. 2010. View Article : Google Scholar : PubMed/NCBI
27	Zhao D, Tong L, Zhang L, Li H, Wan Y and Zhang T: Tanshinone II A stabilizes vulnerable plaques by suppressing RAGE signaling and NF-κB activation in apolipoprotein-E-deficient mice. Mol Med Rep. 14:4983–4990. 2016. View Article : Google Scholar : PubMed/NCBI
28	Yu Y, Wang L, Delguste F, Durand A, Guilbaud A, Rousselin C, Schmidt AM, Tessier F, Boulanger E and Neviere R: Advanced glycation end products receptor RAGE controls myocardial dysfunction and oxidative stress in high-fat fed mice by sustaining mitochondrial dynamics and autophagy-lysosome pathway. Free Radic Biol Med. 112:397–410. 2017. View Article : Google Scholar : PubMed/NCBI
29	Muniyappa R and Srinivas PR: Dicarbonyl stress and atherosclerosis: Is it all RAGE? Diabetes. 63:3587–3589. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ma WQ, Qu QR, Zhao Y and Liu NF: Association of RAGE gene Gly82Ser polymorphism with coronary artery disease and ischemic stroke: A systematic review and meta-analysis. Medicine (Baltimore). 95:e55932016. View Article : Google Scholar : PubMed/NCBI
31	Watson AM, Li J, Samijono D, Bierhaus A, Thomas MC, Jandeleit-Dahm KA and Cooper ME: Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. Atherosclerosis. 235:444–448. 2014. View Article : Google Scholar : PubMed/NCBI
32	Li Y, Zhu J, Chen L, Hu W, Wang M, Li S, Gu X, Tao H, Zhao B, Ma G and Li K: Genetic predisposition to ischaemic stroke by RAGE and HMGB1 gene variants in Chinese Han population. Oncotarget. 8:100150–100164. 2017.PubMed/NCBI